检索结果-南通市图书馆

Neoadjuvant camrelizumab(an anti-PD-1 antibody)plus chemotherapy or apatinib(a VEGFR-2 inhibitor)for initially unresectable stage II–III non-small-cell lung cancer:a multicentre,two-arm,phase 2 exploratory study

在线全文

学校读者我要写书评

暂无评论

Signal Transduction and Targeted Therapy 2024年第7期9卷 3015-3023页

作者： Haoran Xia Han Zhang Zheng Ruan Huibiao Zhang Liangdong Sun Hezhong Chen Yongxin Zhou Lele Zhang Dongliang Bian Xinsheng Zhu Jing Zhang Fenghuan Sun Huansha Yu Nan Song Xiaogang Liu Yuming Zhu Haiping Zhang Wenxin He Jian Chen Jie Yang Guohan Chen Shiliang Xie Dongfang Tang Xiaomiao Zhang Liang Duan Deping Zhao Qinchuan Li Peng Zhang gening jiang Department of Thoracic Surgery Shanghai Pulmonary HospitalTongji University School of MedicineShanghaiChina Department of Thoracic Surgery Shanghai General HospitalShanghai Jiao Tong University School of MedicineShanghaiChina Department of Thoracic Surgery Huadong Hospital Affiliated to Fudan UniversityShanghaiChina Department of Thoracic Surgery Changhai HospitalNaval Medical UniversityShanghaiChina Department of Thoracic-Cardiovascular Surgery Tongji HospitalTongji University School of MedicineShanghaiChina Central Laboratory Shanghai Pulmonary HospitalTongji University School of MedicineShanghaiChina Experimental Animal Center Shanghai Pulmonary HospitalTongji University School of MedicineShanghaiChina Department of Oncology Shanghai Pulmonary HospitalTongji University School of MedicineShanghaiChina Department of Thoracic Surgery Shanghai East HospitalTongji University School of MedicineShanghaiChina

This multicentre,two-arm,phase 2 study aimed to explore the efficacy and safety of neoadjuvant camrelizumab plus chemotherapy or apatinib in patients with initially unresectable stage II–III non-small-cell lung cancer(NSCLC).Eligible patients regardless of PD-L1 expression received neoadjuvant camrelizumab 200 mg and platinum-doublet chemotherapy every 3 weeks(arm A)or those with PD-L1-positive tumors received neoadjuvant camrelizumab and apatinib 250 mg once daily(arm B),for 2–4 cycles,followed by *** primary endpoint was major pathological response(MPR)*** patients in arm A and 21 in arm B were *** rates were 50.0%(15/30)in arm A and 42.9%(9/21)in arm B,with all patients achieving R0 *** these patients,the MPR and pathological complete response rates were both 20.0%(95%CI 4.3–48.1)in arm A and were 55.6%(95%CI 21.2–86.3)and 11.1%(95%CI 0.3–48.2)in arm B,*** corresponding objective response rates were 33.3%(95%CI 11.8–61.6)and 55.6%(95%CI 21.2–86.3).With a median follow-up of 22.4 months(95%CI 19.0–26.0),the median event-free survival was not reached(NR;95%CI 13.6-NR)in arm A and 16.8 months(95%CI 8.6-NR)in arm *** 3 or above treatment-related adverse events occurred in eight(26.7%)patients in arm A and three(14.3%)in arm *** analysis showed baseline TYROBP expression was predictive of treatment response in arm *** camrelizumab plus chemotherapy or apatinib exhibits preliminary efficacy and manageable toxicity in patients with initially unresectable stage II–III NSCLC.

关键词： Surgery chemotherapy treatment

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

数字病理学与肺癌研究进展

中华胸心血管外科杂志 2024年第7期40卷 423-429页

作者：郭奇佶沈子贇武春燕姜格宁张鹏同济大学附属上海市肺科医院胸外科上海200433 同济大学附属上海市肺科医院病理科上海200433

肺癌是全球最常见的癌症类型之一,早期发现和精准诊断在肺癌诊治中至关重要。然而,传统的病理学诊断方法存在诸多局限性,包括诊断过程的繁琐性和结果的难以统一性。相比于传统病理学,数字病理学通过数字化病理信息,与人工智能结合,能实... 详细信息

肺癌是全球最常见的癌症类型之一,早期发现和精准诊断在肺癌诊治中至关重要。然而,传统的病理学诊断方法存在诸多局限性,包括诊断过程的繁琐性和结果的难以统一性。相比于传统病理学,数字病理学通过数字化病理信息,与人工智能结合,能实现快速且精准的辅助诊断,并可深入探索患者的肿瘤特征和微环境信息,有望为肺癌的精准诊疗提供支持。本文对近年来数字病理学在肺癌诊断、分期、治疗和预后等方面的应用进行了阐述,并对当前数字病理学面临的挑战进行了相应的探讨。

关键词：病理学

Outcomes of patients awaiting lung transplantation after the implementation of donation after brain death at a single Chinese center

在线全文

学校读者我要写书评

暂无评论

Frontiers of Medicine 2022年第5期16卷 760-765页

作者： Yuling Yang Xinnan Xu Ming Liu Yanfeng Zhao Yongmei Yu Xiaogang Liu Chang Chen gening jiang Wenxin He Department of Thoracic Surgery Shanghai Pulmonary HospitalSchool of MedicineTongji UniversityShanghai 200092China Department of Cardiothoracic Surgery Zhangzhou Affiliated Hospital of Fujian Medical UniversityZhangzhou 363000China

oluntary contribution has become the only source of donor lungs in China since *** elaborate the outcomes of patients awaiting lung transplantation(LTx)after the implementation of donation after brain death,we performed a retrospective study that encompassed 205 patients with end-stage lung disease who registered for LTx at Shanghai Pulmonary Hospital from January 1,2015 to January 1,2021.A total of 180 patients were enrolled in the *** median waiting time was 1.25 *** lung disease(ILD)(103/180,57.2%)and chronic obstructive pulmonary disease(COPD)(56/180,31.1%)were the most common diseases in our study *** mean pulmonary artery pressure(mPAP)of patients in the died-waiting group was higher than that of the survivors(53.29+21.71 mmHg vs.42.11+18.58 mmHg,P-0.002).The mortality of patients with ILD(34/103,33.00%)was nearly twice that of patients with COPD(10/56,17.86%)while awaiting LTx(P-0.041).In the died-waiting group,patients with ILD had a shorter median waiting time than patients with COPD after being listed(0.865 months vs.4.720 months,P-0.030).ILD as primary disease and mPAP>35 mmHg were two significant independent risk factors for waitlist mortality,with hazard ratios(HR)of 3.483(95%CI 1.311-9.111;P-0.011)and 3.500(95%CI 1.435-8.536;P=0.006).Hence,LTx is more urgently needed in patients with ILD and pulmonary hypertension.

关键词： lung transplantation donation after brain death waitlist

Diagnosis,treatment,and potential causative mutations of cryptogenic plastic bronchitis

在线全文

学校读者我要写书评

暂无评论

Chinese Medical Journal 2023年第4期136卷 497-498页

作者： Jiuwu Bai Shuo Liang Haiwen Lu Mengting Xiong Lei Shen Dong Yu Yuping Li Li Zhang Ye Gu Chunyan Wu Ping jiang Sen jiang gening jiang Jinfu Xu Department of Respiratory and Critical Care Medicine Shanghai Pulmonary HospitalTongji UniversityShanghai 200433China Department of Thoracic Intensive Care Unit Shanghai Pulmonary HospitalTongji UniversityShanghai 200433China Department of Radiology Shanghai Pulmonary HospitalTongji UniversityShanghai 200433China Department of Endoscopy Shanghai Pulmonary HospitalTongji UniversityShanghai 200433China partment of Pathology Shanghai Pulmonary HospitalTongji UniversityShanghai 200433China Department of Thoracic Surgery Shanghai Pulmonary HospitalTongji UniversityShanghai 200433China

To the Editor:Plastic bronchitis(PB)is a rare pulmonary disease characterized by the production of branching bronchial casts that fill the *** is less common in adults than in children,and occurs after 1%to 4%of Fonta... 详细信息

关键词： airway treatment branching

Selection of candidates for surgery as local therapy among early-stage small cell lung cancer patients: a population-based analysis

在线全文

学校读者我要写书评

暂无评论

Cancer Communications 2018年第1期38卷 63-73页

作者： Kaiqi Jin Kaixuan Zhang Feng Zhou Jie Dai Peng Zhang gening jiang Department of Thoracic Surgery Shanghai Pulmonary HospitalSchool of MedicineTongji UniversityNo.507 Zhengmin RoadShanghai 200433P.R.China

Background:Surgery and radiotherapy are considered local therapies for small cell lung cancer(SCLC).The present study aimed to select candidates for surgery as local therapy among patients with stage I or II SCLC,based on the eighth edition of the TNM classification for lung ***:Patients diagnosed with SCLC between 2004 and 2013 were selected from the Surveillance,Epidemiology,And End Results *** TNM stage of SCLC in these patients was re-classified according to the eighth edition of the TNM classification for lung *** with stage I or II SCLC were included in the present *** survival(OS)and lung cancer-specific survival(LCSS)were separately compared in the different TNM stages between patients who received surgery and radiotherapy as local *** analysis was applied to evaluate multi-ple factors associated with ***:Among the 2129 patients included in the present study,387(18.2%)received surgery,1032(48.5%)under-went radiotherapy as local therapy,154(7.2%)underwent surgery and radiotherapy,and 556(26.1%)did not undergo either surgery or *** patients with T1-2N0(tumor size≤50 mm without positive lymph nodes)dis-ease,patients who underwent surgery had higher 5-year OS and LCSS rates than patients who received radiotherapy(T1N0:46.0%vs.23.8%,P<0.001,and 58.4%vs.36.4%,P<0.001,respectively;T2N0:42.6%vs.24.7%,P=0.004,and 48.8%vs.31.3%,P=0.011,respectively).Multivariate analysis results revealed that surgery was associated with low risk of ***,among T3N0 or T1-2N1(stage IIB)SCLC patients,patients who underwent surgery did not have higher 5-year OS and LCSS rates than patients who received radiotherapy(T3N0:16.2%vs.26.5%,P=0.085,and 28.7%vs.30.9%,P=0.372,respectively;T1-2N1:20.3%vs.29.0%,P=0.146,and 25.6%vs.35.5%,P=0.064,respectively).Conclusions:Based on the assumption that the overwhelming majority of stage I or II SCLC patients who underwent surgery or radiotherapy also received

关键词： Small cell lung cancer Surgery Local therapy Radiotherapy

Ⅲ期可切除与潜在可切除非小细胞肺癌的诊疗进展

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

中华胸心血管外科杂志 2023年第6期39卷 379-384页

作者：沈莹冉戴洁姜格宁张鹏同济大学附属上海市肺科医院胸外科上海200433

Ⅲ期NSCLC的治疗充满了挑战,其最佳治疗策略目前尚无定论。新的治疗药物和治疗手段的出现也在不断改写Ⅲ期可切除/潜在可切除NSCLC的定义。可切除N2-Ⅲ期NSCLC淋巴结通常为散在且边缘清晰,与周围结构无粘连。新辅助治疗联合手术相比于... 详细信息

Ⅲ期NSCLC的治疗充满了挑战,其最佳治疗策略目前尚无定论。新的治疗药物和治疗手段的出现也在不断改写Ⅲ期可切除/潜在可切除NSCLC的定义。可切除N2-Ⅲ期NSCLC淋巴结通常为散在且边缘清晰,与周围结构无粘连。新辅助治疗联合手术相比于根治性放化疗可降低局部复发率。对于N3-Ⅲ期NSCLC,目前指南不推荐手术治疗。但对于局限性N3,并对化疗有持续的反应,通过谨慎筛选,手术治疗也可一试。免疫治疗在局部晚期肺癌患者中的应用已有较多前瞻性临床试验证实了其疗效。新辅助免疫治疗可显著提高主要病理缓解率和病理完全缓解率,使潜在可切除的Ⅲ期NSCLC降期后获得手术机会,并改善远期预后。新辅助免疫治疗后的疗效评估,病理活检较CT检查更可靠。总的来说,多模式新辅助治疗取得的卓越进展将带给潜在可切除Ⅲ期NSCLC患者更多的手术机会及更好的远期预后。

关键词：新辅助治疗边缘清晰病理活检远期预后局部复发率联合手术免疫治疗 NSCLC

基于组织工程技术修复节段性气管缺损的研究进展

在线全文

学校读者我要写书评

暂无评论

中华外科杂志 2022年第1期60卷 104-109页

作者：徐勇高二击段亮姜格宁同济大学附属上海市肺科医院胸外科上海200433

近年来,基于组织工程技术修复节段性气管缺损领域出现了大量新的支架材料、制备技术和构建理念,丰富了组织工程气管的临床转化前景。脱细胞、三维打印、静电纺丝和细胞膜片等技术使组织工程气管软骨化日趋稳定成熟,上皮细胞种植或上皮... 详细信息

近年来,基于组织工程技术修复节段性气管缺损领域出现了大量新的支架材料、制备技术和构建理念,丰富了组织工程气管的临床转化前景。脱细胞、三维打印、静电纺丝和细胞膜片等技术使组织工程气管软骨化日趋稳定成熟,上皮细胞种植或上皮细胞膜片移植加速了组织工程气管的上皮化进程,血供丰富的肌肉筋膜等组织的包裹联合带血管蒂移植修复策略的可靠性也获得了证实。如何整合上述方案,同时实现组织工程气管软骨、上皮及血管组织再生,以期最终实现节段性气管功能重建,尚需进一步研究。

关键词：气管组织工程修复外科手术

在线全文

学校读者我要写书评

暂无评论

表现为磨玻璃样影的早期肺癌

中华外科杂志 2015年第10期53卷 790-793页

作者：姜格宁谢冬同济大学附属上海市肺科医院胸外科 200433

在我国,表现为局灶性磨玻璃样影（GGO）的早期肺癌发病率迅速升高.在高危人群中开展低剂量螺旋CT筛查,有利于疾病的早期诊断.GGO早期肺癌的诊断主要依赖于动态观察胸部CT,PET-CT、术前非手术活检对于纯GGO诊断价值有限,假阴性率高.胸腔... 详细信息

在我国,表现为局灶性磨玻璃样影（GGO）的早期肺癌发病率迅速升高.在高危人群中开展低剂量螺旋CT筛查,有利于疾病的早期诊断.GGO早期肺癌的诊断主要依赖于动态观察胸部CT,PET-CT、术前非手术活检对于纯GGO诊断价值有限,假阴性率高.胸腔镜手术（VATS）是GGO早期肺癌的主流治疗术式,单孔VATS、VATS肺段切除术、机器人辅助VATS及剑突下单孔VATS等是微创手术发展的新方向.GGO的术中定位可综合采用多种模式;预计病灶为原位腺癌、微浸润腺癌或最大径＜2 cm的纯GGO可考虑亚肺叶切除;同期多发GGO需要个体化设计手术方案.

关键词：肺肿瘤诊断胸腔镜检查

在线全文

学校读者我要写书评

暂无评论

肺部多发结节的诊断、分期和治疗现状

中华胸心血管外科杂志 2020年第9期36卷 562-568页

作者：戴洁姜格宁同济大学附属上海市肺科医院胸外科 200433

多原发肺癌(multiple primary lung cancer,MPLC)是指同一个体肺内存在两个或两个以上肺癌病灶,其诊断难点在于与肺癌肺内转移(metastatic nodules)相鉴别。传统MPLC诊断主要基于组织病理学,如今分子生物学检测方法也相继应用于MPLC辅... 详细信息

多原发肺癌(multiple primary lung cancer,MPLC)是指同一个体肺内存在两个或两个以上肺癌病灶,其诊断难点在于与肺癌肺内转移(metastatic nodules)相鉴别。传统MPLC诊断主要基于组织病理学,如今分子生物学检测方法也相继应用于MPLC辅助诊断。关于MPLC治疗的手术方式目前尚无定论,受肿瘤个数、位置以及患者心肺储备功能等多方面因素的影响。本文就现今MPLC的诊断、分期和治疗策略进行系统综述。

关键词：肺癌病灶多原发肺癌治疗策略组织病理学治疗现状辅助诊断系统综述 MPLC